Amgen said that it will seek an injunction to prevent Roche from commercializing Mircera, which is used in the treatment of anemia, in the US in violation of Amgen’s affirmed patent rights. The injunction hearing is scheduled for November 15, 2007.
California-based Amgen said that it “firmly believes Roche’s peg-EPO product provides no clinical or patient benefit over Amgen’s innovative therapies, Epogen and Aranesp.”